Spoken Alpha
IRulya Therapeutics Inc.
Quince Therapeutics develops the AIDE technology platform, a drug-device combination that encapsulates drugs into patients' own red blood cells for improved drug delivery to treat rare diseases. The company's lead candidate, eDSP, failed to meet primary endpoints in a Phase 3 trial for ataxia-telangiectasia and is no longer in development.
IRulya Therapeutics Inc is a Healthcare company operating in Biotechnology with a $32.3M market cap.
QNCX beat consensus EPS by 0.6% in Q2 FY2026, reported Aug 13, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add QNCX, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for QNCX.
$ curl https://api.spokenalpha.com/v1/companies/QNCXFAQ
Spoken Alpha indexes QNCX's earnings call transcripts at https://spokenalpha.com/companies/QNCX. Each call links to attributed speakers and parsed analyst Q&A. IRulya Therapeutics Inc.'s own investor relations page is at https://ir.quincetx.com/.
IRulya Therapeutics Inc. (QNCX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-12.31 | $-33.26 | +63.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-04-09 | $-152.00 | $-45.00 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-0.41 | $-0.18 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-50.00 | $-44.50 | -12.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-65.02 | $-46.50 | -39.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.34 | $-0.23 | -47.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-56.00 | $-20.00 | -100.0% | $168.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-26.00 | $-20.00 | -30.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.64 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-03-31 | $-0.22 | — | — | $36.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-13 | $-0.22 | $-0.28 | +21.4% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.15 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.14 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.34 | $-0.31 | -10.5% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $-0.15 | $-0.29 | +47.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-44.00 | $-56.72 | +22.4% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-102.00 | $-56.05 | -82.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-144.00 | $-111.91 | -28.7% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.78 | $-0.65 | -20.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-10-28 | $-146.00 | $-148.80 | +1.9% | $0 | — | — | EODHD |
Source: EODHD. QNCX reported actuals as published; sparse fields render as —.